This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
Dermira (DERM) Catches Eye: Stock Jumps 12%
by Zacks Equity Research
Dermira (DERM) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.
Company News For Mar 19, 2019
by Zacks Equity Research
Companies in the news are: OSTK, FIS, WP, EW and DERM
Implied Volatility Surging for Dermira (DERM) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Dermira (DERM) stock based on the movements in the options market lately.
Dermira (DERM) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dermira (DERM) delivered earnings and revenue surprises of 20.20% and -10.38%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Dermira (DERM) Q3 Earnings Preview: What to Know Ahead of the Release
by Zacks Equity Research
Dermira (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dermira (DERM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dermira (DERM) delivered earnings and revenue surprises of 0.00% and 0.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval
by Zacks Equity Research
Shares of Dermira, Inc. (DERM) increase about 5% after the FDA approved its excessive underarm sweating drug, Qbrexza.
Are Options Traders Betting on a Big Move in Dermira (DERM) Stock?
by Zacks Equity Research
Investors in Dermira (DERM) need to pay close attention to the stock based on moves in the options market lately.
Dermira's Acne Candidate Fails in Pivotal Trials, Shares Sink
by Zacks Equity Research
Dermira's (DERM) pipeline candidate, olumacostat glasaretil, fails to meet primary endpoints in two pivotal studies, which evaluate its efficacy for treating moderate-to-severe acne vulgaris.
Are Options Traders Betting on a Big Move in Dermira (DERM) Stock?
by Zacks Equity Research
Investors in Dermira (DERM) need to pay close attention to the stock based on moves in the options market lately.